Search Results

Seqirus – a global leader in influenza prevention and a business of CSL Limited - has entered into a multi-year influenza research partnership with the University of Liverpool Pandemic Institute.

https://www.seqirus.com/news/csls-seqirus-and-the-university-of-liverpool-pandemic-institute-launch-collaboration

Seqirus has been on the front line of pandemic preparedness for more than a century. Learn more about our rapid vaccine production capabilities.

https://www.seqirus.com/expertise/influenza/pandemic-response-solutions

Renewal reaffirms longstanding, public-private partnership between Seqirus and the Biomedical Advanced Research and Development Authority (BARDA)

https://www.seqirus.com/news/seqirus-and-us-gov-renew-multi-year-agreement-for-influenza-pandemic-preparedness-and-response

Seqirus is one of the largest influenza vaccine companies in the world, with state-of-the-art manufacturing facilities on three continents. Learn more.

https://www.seqirus.com/manufacturing/global-manufacturing-network

Read the latest news from Seqirus, a world leader in developing and producing influenza vaccines.

https://www.seqirus.com/news

Seqirus brings multifaceted expertise to influenza prevention, employing both egg and cell-based technologies to meet the global community's needs.

https://www.seqirus.com/expertise

Seqirus will develop and evaluate two influenza A(H2Nx) virus vaccine candidates in support of U.S. government pandemic preparedness objectives

https://www.seqirus.com/news/seqirus-awarded-us-government-contract-for-two-influenza-vaccines

The new pre-filled syringe line has received FDA approval and will support influenza vaccine production for the 2022/23 Northern Hemisphere season and beyond.

https://www.seqirus.com/news/seqirus-completes-$156-million-expansion-to-hsp-manufacturing-facility

New facility in Waltham, Massachusetts, will support CSL’s growing R&D portfolio, including the self-amplifying mRNA technology platform.

https://www.seqirus.com/news/seqirus-announces-new-facility-supporting-research-and-development-of-influenza-vaccine-technology

First doses of Seqirus’s enhanced influenza vaccine, destined for the U.K., come off a new high-speed fill-and-finish line in Liverpool.

https://www.seqirus.com/news/high-speed-fill-and-finish-in-liverpool